Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2026 · 10-Q
Revenue$29.79M$29.79M−4.3% vs Q2 2025 Net Income$963.00K$963.00K−73.3% vs Q2 2025 EPS Diluted$0.01$0.01−75.0% vs Q2 2025 Gross Profit$19,314,000−4.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,772,000+121.8% Margins · derivedGross margin64.8%−0.2 pt vs Q2 2025
Operating margin2.4%−7.9 pt vs Q2 2025
Net margin3.2%−8.4 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 4, 2026 · 35 d after period end